Fulcrum Therapeutics (FULC) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 38.6% versus a loss of 67.3%. Over five years, FULC leads with a -75.5% price change compared with -86.1% for RLMD. Fulcrum Therapeutics is the larger company by market cap ($281.8 million vs $279.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | RLMD |
|---|---|---|
| Share price | $3.69 | $2.62 |
| Market cap | $281.85M | $279.54M |
| 1-day change | -0.54% | -15.76% |
| YTD return | -67.37% | -45.76% |
| 1-year return | -67.32% | -38.64% |
| 5-year return | -75.50% | -86.09% |
| EPS (TTM) | $-1.04 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-74.88M | $-57.39M |
| 52-week high | $15.74 | $8.00 |
| 52-week low | $2.83 | $2.60 |
| Distance from 52-week high | -76.56% | -67.25% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -0.54% | +310.31% |
| Average volume | 1.37M | 1.45M |
| Shares outstanding | 76.38M | 106.69M |
| Employees | 55 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed FULC by 28.7 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
FULC vs RLMD FAQ
Which is bigger, Fulcrum Therapeutics or Relmada Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $281.85M compared with $279.54M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, FULC or RLMD?
RLMD returned -38.64% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.